NVS sentiment intelligence

Novartis AG (NVS): 7 Best Longevity and Anti-Aging Stocks to Buy

Tone

Positive 66/100

Event

Market update

Published

22 Jun 2026 13:10

Source

Market source

Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win

Novartis is seeing positive results from its $12 billion acquisition of Avidity Biosciences, with promising biomarker findings for its RNA-based medicine delpacibart braxlosiran (del-bax) in patients with facioscapulohumeral muscular dystrophy (FSHD). The Phase 1/2 FORTITUDE stud

Tone

Positive 91/100

Event

Deals and strategy

Published

12 Jun 2026 11:39

Source

BioSpace

Novartis RNA Therapy Del-Brax Shows Success in Muscular Dystrophy Trial

Novartis's RNA therapy, del-brax, has demonstrated success in a Phase 1/2 trial for facioscapulohumeral muscular dystrophy (FSHD) by reducing key biomarkers of muscle damage. The company believes del-brax could be the first disease-modifying treatment for FSHD and is currently en

Tone

Positive 75/100

Event

Market update

Published

12 Jun 2026 11:39

Source

Intellectia AI

Novartis posts trial win for muscle disease drug

Novartis announced that its RNA therapy, braxlosiran (del-brax), acquired through its acquisition of Avidity Biosciences, succeeded in a Phase 1/2 trial for facioscapulohumeral muscular dystrophy, a rare neuromuscular disease. The drug is designed to address the abnormal expressi

Tone

Positive 72/100

Event

Deals and strategy

Published

12 Jun 2026 10:39

Source

Seeking Alpha

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

Novartis presented data from the RemIND trial at the EAACI Congress, showing that Rhapsido® (remibrutinib) met its primary endpoints across the three most common chronic inducible urticaria (CIndU) subtypes, making it the first treatment to demonstrate efficacy in a global Phase

Tone

Positive 74/100

Event

Market update

Published

12 Jun 2026 09:39

Source

GlobeNewswire

TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Raises Target Price to $180

TD Cowen has reiterated its Hold rating on Novartis AG (NVS.US) and increased its price target for the company's stock to $180. This adjustment reflects the analyst firm's updated outlook on Novartis's financials and market position.

Tone

Positive 66/100

Event

Analyst action

Published

12 Jun 2026 08:10

Source

Moomoo

Novartis says rare muscle disease drug shows promise in early trial

Novartis announced that its experimental drug, del-brax, acquired through its takeover of Avidity, showed promise in an early-to-mid-stage study for facioscapulohumeral muscular dystrophy (FSHD). The drug reduced disease-linked blood markers and muscle damage signs, suggesting it

Tone

Positive 74/100

Event

Market update

Published

11 Jun 2026 21:41

Source

Reuters

Novartis AG Stock (NVS) Moved Up by 4.20% on Jun 11: What Investors Need To Know

Novartis AG (NVS) saw its stock rise by 4.20% on June 11, driven by positive results from its FORTITUDE Phase I/II study for del-brax, an investigational drug for facioscapulohumeral muscular dystrophy (FSHD). This positive news, along with reiterated buy ratings from analysts an

Tone

Positive 73/100

Event

Regulatory and legal

Published

11 Jun 2026 18:15

Source

TradingKey

Novartis Reports Positive Data for Neuromuscular Disorder Drug

Novartis announced positive data from the biomarker cohort of its FORTITUDE phase I/II study for delpacibart braxlosiran (del-brax), an investigational therapy for facioscapulohumeral muscular dystrophy (FSHD). The study met its primary and secondary endpoints, showing reductions

Tone

Positive 73/100

Event

Regulatory and legal

Published

11 Jun 2026 17:11

Source

TradingView

Novartis (NVS) reports del-brax FSHD Phase I/II biomarker success, Phase III underway

Novartis announced that its investigational therapy delpacibart braxlosiran (del-brax) successfully met primary and key secondary biomarker endpoints in the FORTITUDE Phase I/II study for facioscapulohumeral muscular dystrophy (FSHD), showing reduced KHDC1L and creatine kinase le

Tone

Positive 73/100

Event

Regulatory and legal

Published

11 Jun 2026 12:11

Source

Stock Titan

Novartis and Orionis get stuck in with new “molecular glue” R&D deal worth up to $1.4bn

Novartis has expanded its agreement with Orionis in a deal potentially worth $1.4 billion to develop "molecular glue" drugs targeting elusive proteins. This collaboration will leverage Orionis's Allo-Glue platform and AI-driven discovery engine to identify and optimize small mole

Tone

Positive 70/100

Event

Deals and strategy

Published

11 Jun 2026 12:11

Source

European Biotechnology Magazine

Novartis delpacibart braxlosiran (del-brax) Phase I/II

Novartis announced that its delpacibart braxlosiran (del-brax) Phase I/II FORTITUDE study met its primary and key secondary endpoints, showing reductions in KHDC1L and creatine kinase levels in patients with facioscapulohumeral muscular dystrophy (FSHD). This indicates strong tar

Tone

Positive 91/100

Event

Market update

Published

11 Jun 2026 05:09

Source

GlobeNewswire

Novartis Reports Positive Biomarker Data for Del-Brax in Muscular Dystrophy Study

Novartis has reported positive biomarker data for its drug candidate delpacibart braxlosiran (del-brax) from a Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD). The study successfully met its primary biomarker endpoint, indicating a promising step forward in the

Tone

Positive 74/100

Event

Market update

Published

11 Jun 2026 05:09

Source

marketscreener.com

Novartis AG stock (CH0012005267): pharma heavyweight digests Sandoz spin-off and eyes next growth wa

Novartis AG has successfully transitioned into a focused innovative medicines company after spinning off its Sandoz generics unit. The company is now concentrating on high-value prescription drugs, supported by a strong pipeline and a strategy to enhance operational efficiency. W

Tone

Positive 70/100

Event

Market update

Published

09 Jun 2026 17:10

Source

AD HOC NEWS

NOVARTIS AG : Deutsche Bank remains its Buy rating

Deutsche Bank has reiterated its "Buy" rating for Novartis AG, maintaining a target price of CHF 135 for the stock. This recommendation was issued by Emmanuel Papadakis in a research note.

Tone

Positive 72/100

Event

Analyst action

Published

09 Jun 2026 04:04

Source

www.marketscreener.com

Novartis AG stock (CH0012005267): oncology focus and AI deals keep investors watching

Novartis AG is maintaining its investor appeal through a sharpened focus on oncology, immunology, and cardiovascular diseases, coupled with strategic investments in AI and digital drug discovery. The company operates as an innovation-driven pharmaceutical group with a strong ther

Tone

Positive 72/100

Event

Market update

Published

08 Jun 2026 17:09

Source

AD HOC NEWS

Novartis AG (NVS) Stock Analysis: Evaluating Growth Potential With A 3.15% Upside

Novartis AG (NVS) is analyzed as a stable pharmaceutical giant with a market capitalization of $284.61 billion, offering a 3.18% dividend yield and a potential upside of 3.15% based on analyst consensus. Despite a slight revenue decline, the company demonstrates robust financial

Tone

Positive 66/100

Event

Earnings

Published

08 Jun 2026 10:17

Source

DirectorsTalk Interviews

Novartis to present Rhapsido data at allergy congress

Novartis (NYSE: NVS) is set to present data from 10 research abstracts at the 2026 European Academy of Allergy and Clinical Immunology Congress. The presentations will focus on Rhapsido (remibrutinib), its BTK inhibitor, covering its effectiveness in chronic inducible urticaria a

Tone

Positive 67/100

Event

Market update

Published

08 Jun 2026 07:09

Source

StreetInsider